Sarepta Therapeutics (SRPT) EBT (2010 - 2026)

Sarepta Therapeutics' EBT history runs 17 years deep, the most recent figure standing at $343.2 million for Q1 2026.

• On a quarterly basis, EBT rose 189.48% year-over-year to $343.2 million in Q1 2026; TTM through Mar 2026 was $24.5 million, a 114.9% increase from a year earlier, with the FY2025 full-year figure at -$702.2 million, down 369.28% from the prior year.
• EBT advanced to $343.2 million in Q1 2026 per SRPT's latest filing, from -$278.3 million in the prior quarter.
• Across five years, EBT topped out at $343.2 million in Q1 2026 and bottomed at -$512.7 million in Q1 2023.
• The 5-year median for EBT is -$14.6 million (2023), against an average of -$51.2 million.
• Biggest YoY gain for EBT was 1031.6% in 2025; the steepest drop was 1025.3% in 2025.
• Year by year, EBT stood at $337.3 million in 2022, then sank by 88.03% to $40.4 million in 2023, then jumped by 325.41% to $171.7 million in 2024, then tumbled by 262.04% to -$278.3 million in 2025, then surged by 223.31% to $343.2 million in 2026.
• Per Business Quant, the three latest SRPT EBT figures stand at $343.2 million (Q1 2026), -$278.3 million (Q4 2025), and -$194.0 million (Q3 2025).